Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 3,759 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 57
States / cities: Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 45 more

Conditions: Breast Cancer
Interventions: OneMark device; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Immunotherapy, Palliative Radiation Therapy, Spatially-fractionated Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer
Interventions: mutation analysis, tumor replication error analysis; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 44
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 27 more

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pediatric Pain, Chronic Pain, Widespread, Musculoskeletal Pain
Interventions: Graded Exposure Therapy (GET Living), Multidisciplinary Pain Management (MPM); Behavioral
Lead sponsor: Laura E Simons; Other
Eligibility: 8 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions: AMXT1501, DFMO; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more

Conditions: Cytomegalovirus Infections
Interventions: Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution); Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Primary Renal Cancer
Interventions: MRI-guided linear accelerator, Magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT); Device · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Herceptin, NeuVax vaccine, GM-CSF; Drug
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 29
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more

Conditions: Myeloma, Plasma-Cell, Myeloma-Multiple
Interventions: Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 73 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: B-Cell Malignancies
Interventions: Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Detroit, Michigan + 4 more

Conditions: Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions: Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil; Biological · Other · Procedure + 1 more
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: VS-6766/avutometinib, Cetuximab, Pill Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Esophageal Cancer
Interventions: ZD1839; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Phenylketonuria
Interventions: BMN 165; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: La Jolla, California • Oakland, California • Aurora, Colorado + 28 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Multiple Myeloma
Interventions: Radiation; Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Food Hypersensitivity
Interventions: Peanut SLIT, Placebo SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ulcerative Colitis, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions: ropinirole controlled-release (REQUIP CR) for RLS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more

Search by objective public record fields.

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Gene Testing in Patients With Colon Cancer

Y-90 Treatment Response Using Transarterial Radioembolization

GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain

Oral AMXT 1501 Dicaprate in Combination With DFMO

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Phase I/II Thymus Transplantation With Immunosuppression #950

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Hypofractionation (Radiation) Trial for Multiple Myeloma

A Study of Sublingual Immunotherapy in Peanut-allergic Children

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's